[Fetal RHD in maternal plasma in prenatal follow-up].
Since the beginning of RHD genotyping in maternal plasma, no Rh D positive baby was diagnosed RHD negative in our institution. Genotyping from circulating DNA in maternal plasma is as efficient as genotyping on amniocyts but without the associated risks. We propose a prophylactic injection based on fetal genotyping RHD in maternal blood with 300 microg anti-D immunoglobulin at 28 weeks of amenhorrea in all of Rh D negative pregnant women whitch fetuses positive RHD.
Dricot
J F
JF
Service de gynécologie-obstétrique, CHR Citadelle, Liège. jf_dricot@hotmail.com
Minon
J M
JM
Schaaps
J P
JP
Dewez
P
P
Foidart
J M
JM
D004247:DNA / Q000097:blood; D005091:Exons / Q000235:genetics; D005260:Female; D005312:Fetal Blood / Q000737:chemistry*; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007231:Infant, Newborn; D008297:Male; D011237:Predictive Value of Tests; D011247:Pregnancy / Q000097:blood*; D011295:Prenatal Care; D012203:Rh Isoimmunization / Q000517:prevention & control; D012204:Rh-Hr Blood-Group System / Q000032:analysis / Q000235:genetics*; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use; D012680:Sensitivity and Specificity
D007155:Immunologic Factors; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin; D004247:DNA